Altered gut microbiota composition due to anatomical and metabolic changes after RYGB
Target Population
Adults aged 18–65 undergoing RYGB surgery with BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities
Care Setting
Bariatric surgery centers and outpatient clinical follow-up
Key Highlights
Nearly 50% of RYGB patients experience long-term GI symptoms including diarrhea, cramps, bloating, and bowel urgency.
Postoperative gut microbiota shifts include increases in Fusobacteria and Streptococcus subspecies and decreases in Bifidobacterium and Firmicutes.
GI symptoms severity may be linked to pre- and postoperative gut microbiota composition, with potential involvement of oral microbiota strains colonizing the lower gut.
Guideline-Based Recommendations
Diagnosis
Use the Gastrointestinal Quality of Life Index (GIQLI) questionnaire to assess GI symptoms pre- and post-RYGB.
Define low GI quality of life as GIQLI score <126 and monitor changes over time to evaluate symptom progression.
Management
Consider dietary advice and pre- or probiotic interventions targeting gut microbiota alterations to manage GI symptoms.
Monitor nutritional intake using dietary diaries to assess macronutrient consumption influencing microbiota.
Monitoring & Follow-up
Perform longitudinal follow-up with GIQLI questionnaires annually post-surgery.
Collect fecal samples preoperatively and at 1-year postoperatively for microbiota analysis.
Risks
High prevalence of chronic GI symptoms post-RYGB may reduce quality of life and daily functioning.
Altered gut microbiota may contribute to persistent GI complaints, complicating postoperative recovery.
Patient & Prescribing Data
67 adult RYGB patients from the BARIA longitudinal bariatric cohort study.
Machine learning models suggest gut microbiota composition before and after surgery may predict GI symptom severity, indicating potential for microbiota-targeted therapies.
Clinical Best Practices
Screen RYGB patients routinely for GI symptoms using validated questionnaires like GIQLI.
Incorporate gut microbiota profiling in research and potentially clinical evaluation to understand symptom etiology.
Advise patients on dietary modifications and consider pre- or probiotic supplementation based on microbiota findings.
Ensure ethical approval and informed consent for longitudinal microbiota and symptom monitoring studies.
by Madelief Wijdeveld, Nienke van Olst, Eduard W. J. van der Vossen, Maurits de Brauw, Yair I. Z. Acherman, Marcus C. de Goffau, Victor E. A. Gerdes, Max Nieuwdorp
